Company · Newsroom

What’s new at Verantos.

News, announcements, and company updates.

Upcoming

Verantos to present at the opening session of DIA’s Real World Evidence Conference October 2025 · component demo, visible in Copy review only — renders on the page only while an event is genuinely upcoming

What’s new at Verantos.

Verantos ranked number 444th fastest-growing company in North America on the 2025 Deloitte Technology Fast 500™

Verantos to present at the opening session of DIA’s Real World Evidence Conference

Verantos presents practical approaches in high-validity real-world evidence generation at ISPE’s 41st Annual Meeting

Verantos named to Inc. 5000 list for the fourth consecutive year (2025)

Verantos and Amgen publish on high-validity RWE in Epidemiology

Verantos Ranked Number 319 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500

Verantos presents at DIA’s Real-World Evidence Conference 2024

Verantos named to Inc. 5000 list of fastest-growing American companies for third consecutive year (2024)

Distinguished experts join Verantos inflammatory bowel disease advisory panel

Verantos launches Alzheimer's Disease Pragmatic Registry to support high-validity real-world evidence generation

Verantos presents abstract on high-validity RWE at ISPOR

Verantos launches Inflammatory Bowel Disease Pragmatic Registry to support high-validity real-world evidence generation in ulcerative colitis, Crohn's disease

National Institutes of Health (NIH) shares insights on the origin of Verantos’ AI-based deep phenotyping

Verantos Announces Partnership with CuriMeta to Advance High-Validity, Real-World Evidence

Verantos presents on artificial intelligence and real-world evidence at the Economist’s Cell and Gene Therapy Summit

Verantos CEO appointed to the US Health IT Advisory Committee

Verantos and Amgen publish on AI in asthma

Verantos Ranked Number 189th Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500

Non-alcoholic steatohepatitis (NASH) real-world evidence innovation further extends Verantos' lead in artificial intelligence for cardiometabolic conditions

Verantos exhibits at DIA Real-World Evidence Conference

Amgen presents abstract validating use of AI and advanced data sources for asthma at CHEST

Forbes article highlights how patients can benefit from high-validity RWE generation using AI

Verantos exhibits at ICPE 2023

Verantos named to Inc. 5000 list of fastest-growing American companies for second consecutive year (2023)

AI-based heart failure phenotyping enables high-validity evidence

Groundbreaking work in migraine real-world evidence extends Verantos' lead in artificial intelligence for neurology

Verantos presents DIA session on best practices for ensuring high-validity RWE

Verantos enables high-validity RWE for “soft outcomes” in migraine

Lundbeck publishes in Neurology on AI in migraine RWE

The Evidence Base covers Pragmatic Registry launch

Verantos launches Asthma Pragmatic Registry

Verantos launches Pragmatic Registry to support high-validity real-world evidence generation

HealthBiz interviews Verantos CEO

Verantos exhibiting at Access 2023 Annual Meeting

Verantos December 2022 Newsletter

Lundbeck and Verantos publish on high-validity migraine real-world evidence

Dan Riskin to present at PMWC 2023

Strength in Numbers: Distilling RWE into clinical practice

How Do I Participate In The Legislative Process?

Verantos launches platform for high-validity RWE

Verantos Fall 2022 Newsletter

Verantos named to 2022 Inc. 5000

FDA highlights Verantos in NIH Pragmatic Trials Collaboratory webinar

Verantos presents at BIO

Verantos enables high-validity RWE in migraine

Verantos July 2022 Newsletter

Verantos provides RWE leadership in CEO roundtable

Healthcare AI Bias: Reasons and Resolutions

Verantos to present early findings from TRUST at BIO

Verantos May 2022 Newsletter

Healthcare Technology Leader Joins Verantos′ Strategic Advisory Board

Verantos will be at ISPOR 2022

Verantos panel at DIA

Verantos March 2022 Newsletter

Verantos January 2022 Newsletter

Use of Real World Evidence (RWE) and AI to enable better clinical care

Leading with Authenticity

How real-world evidence, AI will enable better care

Verantos Announces Breakthrough in Non-alcoholic Steatohepatitis Real-world Evidence

Using Real-World Evidence (RWE) & AI to Enable Better Clinical Care

Pharma & Big Data: New Heights Beckon

2022 forecast: 7 predictions for what lies ahead for health equity

Verantos November 2021 Newsletter

How Real-World Evidence Is Shaping The Future Of Healthcare

Verantos Named "BioInformatics Company of the Year" by BioTech Breakthrough

Verantos September 2021 Newsletter

How To Diversify Trials: Recruitment Protocols, Other Approaches

NPR: How to Decipher Which Healthcare Startups Can Be Trusted

Verantos Announces Collaboration with Nashville Biosciences to Power Advanced Real-World Evidence Studies

Dan Riskin On How Verantos’ Technology Can Make An Important Impact In Our Overall Wellness

Verantos June 2021 Newsletter

Verantos Receives Grant Award from the National Science Foundation

Verantos and Lundbeck Announce Partnership for Migraine Care Implementing Advanced Real-World Evidence

Verantos May 2021 Newsletter

Verantos Announces Strategic Partnership with Datavant to Power Additional Insights in its Regulatory-Grade Real World Evidence Studies

Verantos and Amgen Announce Collaboration in Advanced Real-World Evidence

AI: The next great augmentation tool

Verantos receives Food and Drug Administration (FDA) support to demonstrate advanced approaches to real-world evidence

Verantos announces commercial availability of regulatory-grade EHR-based study solution